Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

Autor: Lourdes Farre, Gabriela Sanz, Neus Ruiz-Xivillé, Manuel Castro de Moura, Juan Francisco Martin-Tejera, Samuel Gonçalves-Ribeiro, Maria Martinez-Iniesta, Monica Calaf, Jose Luis Mosquera, José Ignacio Martín-Subero, Isabel Granada, Manel Esteller, Eva Domingo-Domenech, Fina Climent, Alberto Villanueva, Anna Sureda

Publikováno v: Disease Models & Mechanisms
article-version (VoR) Version of Record
Dipòsit Digital de la UB
Universidad de Barcelona
Disease Models & Mechanisms, Vol 14, Iss 7 (2021)

Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::bbde2d5324a2db66a5aa617fcc12d0a4
https://pubmed.ncbi.nlm.nih.gov/33988237